Methods Of Treating Chronic Kidney Disease With Dapagliflozin
Patent No. EP4188389 (titled "Methods Of Treating Chronic Kidney Disease With Dapagliflozin") was filed by Astrazeneca on Apr 1, 2021. The application was issued on Sep 17, 2025.
Patent Summary
Treatment of chronic kidney disease (CKD) in patients with and without type 2 diabetes using sodium glucose co-transporter type 2 (SGLT2) inhibitors, such as dapagliflozin, to reduce CKD progression, cardiovascular events, and mortality. The treatment also prevents or delays the onset of type 2 diabetes in prediabetic patients.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4188389
- Application Number
- EP21716724A
- Filing Date
- Apr 1, 2021
- Status
- Granted And Under Opposition
- Aug 15, 2025
- Publication Date
- Sep 17, 2025
- External Links
- Slate, Register , Google Patents